FX.co ★ Viking Therapeutics Reports Positive Data From Phase 1b Study Of VK0214 In X-ALD

Viking Therapeutics, Inc. (VKTX) announced encouraging results from their Phase 1b trial of VK0214 on Wednesday, involving participants with X-linked adrenoleukodystrophy (X-ALD). X-ALD is a rare, often fatal metabolic disorder that involves the deterioration of protective barriers surrounding the brain and nerve cells. The Phase 1b trial focused on assessing the safety and tolerability of VK0214 in adult male patients diagnosed with the adrenomyeloneuropathy (AMN) variant of X-ALD. Participants received a once-daily dose over a 28-day period. The findings indicated that VK0214 was both safe and well-tolerated throughout the duration of the study. Notably, there were substantial reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, compared to the placebo group. VLCFAs are recognized as key biomarkers in individuals with X-ALD.